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Abstract
Background: Pharmacovigilance programmes can monitor and help ensure the safe use of medicines that are critical 
to the success of global public health programmes. The widespread deployment of artemisinin-based combination 
therapy (ACT) by national malaria control programmes as part of the overall Global Malaria Action Plan for malaria 
control to elimination and eradication makes ACT an excellent candidate for pharmacovigilance activities. In 2008, The 
Roll Back Malaria partnership issued guidelines for inclusion of pharmacovigilance in Global Fund and other related 
proposals. In light of this recommendation and the rapid scale-up of ACT worldwide, an analysis of Global Fund Round 
8 proposals and the President's Malaria Initiative (PMI) 2009 Malaria Operational Plans was conducted to assess if and 
how pharmacovigilance has been incorporated into countries' national malaria plans and donor budget requests.
Methods: The Global Fund - Malaria Round 8 proposals for the 26 countries and the PMI Malaria Operational Plans 
(MOPs) for fiscal year 2009 for the 15 countries that were approved and received funding from either the Global Fund - 
Malaria Round 8 or PMI were accessed through the programme websites. The analysis consisted of conducting word 
counts and key word in context analyses of each proposal and plan.
Results: Twelve out of 26 (46%) of the Global Fund proposals mentioned that established pharmacovigilance systems 
were present in their countries. Four of the fifteen PMI MOPs (27%) mentioned that established pharmacovigilance 
systems were present in their countries. Only seven of the 26 (27%) Global Fund proposals included a request for 
funding for new or current pharmacovigilance activities. Seven of 15 (47%) MOPs included a request for funding for 
pharmacovigilance activities.
Conclusions: There were relatively few requests for funding for pharmacovigilance activities, demonstrating a lack of 
emphasis placed on pharmacovigilance systems in recipient countries. The findings stress the need for more active 
direction to strengthen active surveillance and passive adverse event reporting systems to augment the issuance of 
guidance documents.
Background
Malaria is a major global public health concern with over
250 million cases annually resulting in close to one mil-
lion deaths, mostly among young children in sub-Saharan
Africa [1]. This devastating disease can be prevented and
managed through the proper use of anti-malarial medi-
cines, long-lasting insecticide-treated nets, and indoor
residual spraying. The evidence-base for each of these
strategies has grown in recent years and has led to the
adoption of country policies and guidelines intended to
avert malaria cases and save lives [2]. Malaria control
efforts have been strengthened by increased funding
from numerous donor groups and agencies. Among the
largest donor organizations in combating malaria are The
Global Fund to Fight AIDS, Tuberculosis and Malaria
(Global Fund) and the United States' President's Malaria
Initiative (PMI). Increases in donor support combined
with renewed drug development efforts and successes in
scale-up programmes have resulted in greater access to
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newer treatments for malaria, such as artemisinin-based
combination therapy (ACT).
Introducing newer medicines with limited real-world
safety data, such as ACT, into poorly funded health care
systems combined with large scale-up access pro-
grammes make it imperative to monitor their use and
safety. Without efforts to assure that accurate and timely
safety information is generated and used, significant
resources could be wasted, poor quality products could
cause harm, and suboptimal use of medicines could
adversely affect patient outcomes and fall short of the
goal of improved access to quality, efficacious medicines
at affordable cost [3-5]. Pharmacovigilance is the science
and activities relating to the detection, evaluation, under-
standing and prevention of adverse reactions to medi-
cines or any other medicine-related problems and is
critical for evaluating and characterizing a drug's risk-
benefit profile after being released onto the market [6].
Pharmacovigilance is important in the resource-con-
strained settings because patients may present different
susceptibility profiles for adverse events due to genetic,
nutritional, co-morbidity, and other differences and many
resource-limited countries lack some or all of the World
Health Organization's (WHO) basic elements of a phar-
macovigilance system [7,8]. The conduct of pharmacovig-
ilance includes passive reporting of adverse drug events,
focused active surveillance studies, the use of confirma-
tory pharmacoepidemiologic studies, and risk mitigation
and risk communication strategies [9]. One of the recom-
mended active surveillance approaches to evaluate sys-
tematically the postmarketing safety of medicines used
during pregnancy is the use of pregnancy exposure regis-
tries, a strategy for pharmacovigilance recommended for
pr oducts,  su c h as  A CT , lik e l y t o be  used during  pr eg-
nancy [10-13].
Since the greatest burden of malaria falls upon low- and
middle-income countries with inadequate pharmacovigi-
lance systems in place, it is imperative that programmes
to support malaria case management also include provi-
sions for pharmacovigilance surveillance. In recognition
of this need, the Roll Back Malaria partnership (RBM)
issued guidance to countries applying for malaria funding
in mid-2008 for the conduct and use of pharmacovigi-
lance within donor-supported programmes. RBM issued
recommendations and a template that strongly encour-
aged all countries to include pharmacovigilance in their
national malaria plans as well as to budget for a pharma-
covigilance component in any Global Fund or other grant
proposal for rapid scale-up of use of ACT [14,15]. In light
of these recommendations to increase the attention and
funding for pharmacovigilance specific to ACT, Global
Fund Round 8 proposals that were due in mid-2008 were
analysed. In addition, PMI 2009 Malaria Operational
Plans that were due prior to October 2008 were examined
to assess if and how pharmacovigilance has been incorpo-
rated into countries' national malaria plans and requests
made of this major donor.
Methods
The Global Fund - Malaria Round 8 2008 proposals for
the 26 countries and the PMI Malaria Operational Plans
(MOPs) for fiscal year 2009 for the 15 countries were
accessed from the respective programmes' websites in
their entirety (Table 1). All of these proposals were
approved and received funding from either the Global
Fund - Malaria Round 8 or PMI. Word count and Key
Word in Context (KWIC) analyses were conducted on all
sections that could contain pharmacovigilance informa-
tion [16]. In order to evaluate how effectively the RBM
guidance was incorporated into the Global Fund propos-
als, they were examined as well as the PMI MOPs for all
specific references to pharmacovigilance-related activi-
ties, including budget allocations and evidence of integra-
tion of pharmacovigilance into national malaria
programmes. Specific search terms were: pharmacovigi-
lance, drug safety, artemisinin, ACT, active surveillance,
passive surveillance, post-market surveillance, and preg-
nancy registry. Both structural and thematic coding was
conducted [17] by quantifying the pharmacovigilance ref-
erences and analysing them for consistency in their defi-
nitions of aspects of pharmacovigilance systems such as
passive surveillance, active surveillance, and pregnancy
registries. Additionally, content analysis of proposals was
performed by hand and with ATLAS.ti© software [18].
Results
Twelve out of 26 (46%) Global Fund proposals mentioned
that established pharmacovigilance systems were present
in their countries (Table 2). When prompted by section
4.10.4 in the Global Fund Round 8 proposal form to cite
the integration of current pharmacovigilance activities or
to cite future plans, only eight out of 26 countries did so
(31%). None of the Global Fund proposals mentioned
having or planning to develop a pregnancy registry in
their country. Four out of fifteen PMI MOPs (27%) men-
tioned that established pharmacovigilance systems were
present in their countries (Table 2). Only one MOP, from
Uganda, mentioned having or planning to develop a preg-
nancy registry. Four countries had both a MOP and a
Global Fund proposal allowing for comparisons between
proposals: Ghana, Ethiopia, Rwanda, and Tanzania. Table
3 illustrates inconsistencies in the information submitted
by these countries for the PMI MOPs for 2009 and GF
Round 8 Malaria proposals. Ghana and Ethiopia, for
example, mentioned pharmacovigilance in their Global
Fund proposals, but not in the PMI MOP. Tanzania
referred to using previous PMI funds to strengthen phar-
macovigilance systems, but did not describe pharma-Stergachis et al. Malaria Journal 2010, 9:148
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Table 1: Countries included in analyses by type of proposal
Global Fund Round 8 Proposal Country
http://www.theglobalfund.org/grantdocuments/8AFGM_1614_0_full.pdf Afghanistan
http://www.theglobalfund.org/grantdocuments/8BOLM_1627_0_full.pdf Bolivia
http://www.theglobalfund.org/grantdocuments/8BRAM_1632_0_full.pdf Brazil
http://www.theglobalfund.org/grantdocuments/8BURM_1636_0_full.pdf Burkina Faso
http://www.theglobalfund.org/grantdocuments/8CAFM_1645_0_full.pdf Central African Republic
http://www.theglobalfund.org/grantdocuments/8COLM_1652_0_full.pdf Colombia
http://www.theglobalfund.org/grantdocuments/8COMM_1655_0_full.pdf Comoros
http://www.theglobalfund.org/grantdocuments/8COGM_1660_0_full.pdf Congo Republic
http://www.theglobalfund.org/grantdocuments/8ZARM_1658_0_full.pdf DR of Congo
http://www.theglobalfund.org/grantdocuments/8CIVM_1662_0_full.pdf Côte d'Ivoire
http://www.theglobalfund.org/grantdocuments/8ECUM_1668_0_full.pdf Ecuador
http://www.theglobalfund.org/grantdocuments/8ETHM_1672_0_full.pdf Ethiopia
http://www.theglobalfund.org/grantdocuments/8GHNM_1678_0_full.pdf Ghana
http://www.theglobalfund.org/grantdocuments/8HTIM_1685_0_full.pdf Haiti
http://www.theglobalfund.org/grantdocuments/8INDM_1694_0_full.pdf Indonesia
http://www.theglobalfund.org/grantdocuments/8PRKM_1702_0_full.pdf Korea
http://www.theglobalfund.org/grantdocuments/8KGZM_1705_0_full.pdf Kyrgyzstan
http://www.theglobalfund.org/grantdocuments/8NGAM_1730_0_full.pdf Nigeria
http://www.theglobalfund.org/grantdocuments/8PNGM_1735_0_full.pdf Papua New Guinea
http://www.theglobalfund.org/grantdocuments/8RWNM_1744_0_full.pdf Rwanda
http://www.theglobalfund.org/grantdocuments/8SRLM_1756_0_full.pdf Sri Lanka
http://www.theglobalfund.org/grantdocuments/8SWZM_1759_0_full.pdf Swaziland
http://www.theglobalfund.org/grantdocuments/8TAJM_1763_0_full.pdf TajikistanStergachis et al. Malaria Journal 2010, 9:148
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http://www.theglobalfund.org/grantdocuments/8TNZM_1766_0_full.pdf Tanzania
http://www.theglobalfund.org/grantdocuments/8UZBM_1774_0_full.pdf Uzbekistan
http://www.theglobalfund.org/grantdocuments/8ZANM_1782_0_full.pdf Zanzibar
http://www.theglobalfund.org/grantdocuments/8ZIMM_1785_0_full.pdf Zimbabwe
PMI Malaria Operational Plan Country
http://fightingmalaria.gov/countries/mops/fy09/angola_mop-fy09.pdf Angola
http://fightingmalaria.gov/countries/mops/fy09/benin_mop-fy09.pdf Benin
http://fightingmalaria.gov/countries/mops/fy09/ethiopia_mop-fy09.pdf Ethiopia
http://fightingmalaria.gov/countries/mops/fy09/ghana_mop-fy09.pdf Ghana
http://fightingmalaria.gov/countries/mops/fy09/kenya_mop-fy09.pdf Kenya
http://fightingmalaria.gov/countries/mops/fy09/liberia_mop-fy09.pdf Liberia
http://fightingmalaria.gov/countries/mops/fy09/madagascar_mop-fy09.pdf Madagascar
http://fightingmalaria.gov/countries/mops/fy09/malawi_mop-fy09.pdf Malawi
http://fightingmalaria.gov/countries/mops/fy09/mali_mop-fy09.pdf Mali
http://fightingmalaria.gov/countries/mops/fy09/mozambique_mop-fy09.pdf Mozambique
http://fightingmalaria.gov/countries/mops/fy09/rwanda_mop-fy09.pdf Rwanda
http://fightingmalaria.gov/countries/mops/fy09/senegal_mop-fy09.pdf Senegal
http://fightingmalaria.gov/countries/mops/fy09/tanzania_mop-fy09.pdf Tanzania
http://fightingmalaria.gov/countries/mops/fy09/uganda_mop-fy09.pdf Uganda
http://fightingmalaria.gov/countries/mops/fy09/zambia_mop-fy09.pdf Zambia
Table 1: Countries included in analyses by type of proposal (Continued)
covigilance activities in any detail or request funds for
pharmacovigilance in either PMI or Global Fund Round 8
proposal.
The frequency and amount of funding requested for
pharmacovigilance by countries seeking funding for
malaria programmes was also analysed. Seven of the 26
(27%) Global Fund proposals included a request for fund-
ing for pharmacovigilance activities and seven of 15 (47%)
MOPs included a request for funding for pharmacovigi-
lance activities. Of the seven countries that requested
funds for pharmacovigilance in their PMI MOPs for FY
2009, two included pharmacovigilance within a line item
with other treatment and training activities without sepa-
rating out the component costs. Of the proposals that
listed pharmacovigilance projects as an independent line
item, the amount requested ranged from $50,000 toStergachis et al. Malaria Journal 2010, 9:148
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Table 2: Pharmacovigilance mentions in PMI FY 2009 MOPs and in Global Fund Round 8 - Malaria proposals
PMI FY 2009 Countries 
(15 total)
No. of responses 
(% of total)
Global Fund Round 8 
Countries (26 total)
No. of responses 
(% of total)
Country has a Pharmacovigilance 
Programme mentioned in MOP or 
Global Fund proposal
Yes KEN, MDG, MWI, SEN, 4 (27%) BFA, CAF, COL, COM, CIV, 
ETH, GHA, NGA, PNG, UZB, 
ZBR, ZWE
12 (46%)
No AGO, ETH, GHA, LBR 4 (27%) AFG, BOL, BRA, COG, ECU, 
COD, HTI, KGZ, RWA, TJK, 
TZA,
11 (42%)
Initial Phase of Development BEN, MLI, MOZ, RWA, UGA 5 (33%)
No mention in proposal TZA, ZMB 2 (13%) IDN, KOR, SWZ, 3 (12%)
Total Respondents 15 (100%) 26 (100%)
A section is dedicated to 
pharmacovigilance in the MOP or Global 
Fund proposal
Yes LBR, MDG, MWI, MLI, MOZ, 
RWA, SEN, UGA
8 (53%) COL, COM, COG, COD, ETH, 
GHA, NGA, ZBR
8 (31%)
No AGO, BEN, ETH, GHA, KEN, 
TZA, ZMB
7 (47%) AFG, BOL, BRA, BFA, CAF, 
CIV, ECU, HTI, IDN, KOR, 
KGZ, PNG, RWA, SWZ, TJK, 
TZA, UZB, ZWE
18 (69%)
Total Respondents 15 (100%) 26 (100%)
A pregnancy registry is mentioned in the 
MOP or Global Fund proposal
Yes UGA 1 (7%) None 0 (0%)
No/Not mentioned in proposal AGO, BEN, ETH, GHA, KEN, 
LBR, MDG, MWI, MLI, MOZ, 
RWA, SEN, TZA, ZMB
14 (93%) All 26 (100%)
Total Respondents 15 (100%) 26 (100%)
The country requested funds in its MOP 
or Global Fund proposal for 
pharmacovigilance activities:
Yes GHA, MDG, MWI, MLI, 
MOZ, RWA, UGA
7 (47%) CAF, COL, COG, CIV, NGA, 
SWZ, ZBR
7 (27%)Stergachis et al. Malaria Journal 2010, 9:148
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No AGO, BEN, ETH, KEN, LBR, 
SEN, TZA, ZMB
8 (53%) AFG, BOL, BRA, BFA, COM, 
DR of Congo, ECU, ETH, 
GHA, HTI, IDN, KOR, KGZ, 
PNG, RWA, TJK, TZA, UZB, 
ZWE
19 (73%)
Total Respondents 15 (100%) 26 (100%)
Type of Pharmacovigilance surveillance 
mentioned in MOP or Global Fund 
proposal
Passive only LBR, MWI, UGA 3 (20%) BFA, CAF, COL, COM, COG, 
CIV, ETH, NGA, PNG, RWA, 
UZB, ZBR, ZWE
13 (50%)
Active only 0 (0%) 0 (0%)
Both passive and active MDG, MLI, RWA 3 (20%) GHA 1 (4%)
None mentioned AGO, BEN, ETH, GHA, KEN, 
MOZ, SEN, TZA, ZMB
9 (60%) AFG, BOL, BRA, COD, ECU, 
HTI, IDN, KOR, KGZ, SWZ, 
TJK, TZA
12 (46%)
Total Respondents 15 (100%) 26 (100%)
A national agency in charge of 
Pharmacovigilance activities is 
mentioned in MOP or Global Fund 
proposal
Yes GHA, KEN, LBR, MDG, MWI, 
MLI, MOZ, RWA, SEN, UGA, 
ZMB
11 (73%) AFG, BOL, BRA, BFA, CAF, 
COL, COM, COG, CIV, COD, 
ETH, GHA, HTI, IDN, KOR, 
KGZ, NGA, PNG, SWZ, TJK, 
UZB, ZWE
23 (88%)
No/Not mentioned in proposal AGO, BEN, ETH, TZA 4 (27%) ECU, RWA, TZA 3 (12%)
Total Respondents 15 (100%) 26 (100%)
Afghanistan, AFG; Liberia, LBR; Angola, AGO; Angola, AGO; Madagascar, MDG; Benin, BEN; Malawi, MWI; Bolivia, BOL; Mali, MLI; Brazil, BRA; 
Mozambique, MOZ; Burkina Faso, BFA; Nigeria, NGA; Central African Republic, CAF; Papua New Guinea, PNG; Colombia, COL; Republic of Congo, 
COG; Cote D'Ivoire, CIV; Rwanda, RWA; Democratic Republic of Congo, COD; Senegal, SEN; Ecuador, ECU; Swaziland, SWZ; Ethiopia, ETH; 
Tajikistan, TJK; Ghana, GHA; Tanzania, TZA; Haiti, HTI; Uganda, UGA; Indonesia, IDN; Union of Comoros, COM; Kenya, KEN; Uzbekistan, UZB; Korea, 
KOR; Zambia, ZMB; Kyrgyzstan, KGZ; Zanzibar, ZBR
Table 2: Pharmacovigilance mentions in PMI FY 2009 MOPs and in Global Fund Round 8 - Malaria proposals (Continued)
$700,000 for activities over three years (Table 4).
Analysing the amount requested for pharmacovigilance
activities in the Global Fund proposals was not possible
due to the manner in which the budgets are delineated;
costs are grouped by type (human resources, supplies,
etc.) rather than by activity.
Discussion
This study is, to the authors' knowledge, the first pub-
lished systematic analysis of country-level pharmacovigi-
lance activities and plans as contained in malaria control
and prevention proposals submitted to two of the largest
international donor groups. The findings show a lack of
systematic and consistent inclusion of pharmacovigilanceStergachis et al. Malaria Journal 2010, 9:148
http://www.malariajournal.com/content/9/1/148
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activities and requests for funding support in proposals
and in country plans. This lack of consistency in what was
defined and reported as pharmacovigilance across pro-
posals demonstrates the need for stronger efforts to
advance the role and effectiveness of the pharmacovigi-
lance field to support malaria control and prevention pro-
grammes. The analysis also highlights the need for
greater attention to pharmacovigilance in future propos-
als and country plans. Additionally, this analysis can serve
as a baseline for assessing effectiveness of strategies to
strengthen programmes over time.
This analysis, in light of the guidance from RBM issued
in 2008, demonstrates that such a recommendation had
been relatively ineffective and that more is needed to pro-
mote the inclusion of pharmacovigilance activities in
funding proposals. Required inclusion of pharmacovigi-
lance activities in drug procurement proposals and com-
mensurate budget guidance should be explicitly stated in
calls for applications. Recently, as part of the first phase of
the Affordable Medicine Facility for malaria (AMFm) ini-
tiative, the World Health Organization (WHO) and the
Medicines for Malaria Venture (MMV) developed a set of
guidelines and recommendations for countries on how
and what to include in pharmacovigilance sections of
their AMFm proposals [19]. This publication is more
detailed than the previous recommendation issued by
RBM. Representatives from the Global Fund among other
global health initiatives focused on malaria participated
in the creation of this guidance, so the inclusion of phar-
macovigilance activities should be a serious consideration
of future Global Fund Technical Review Panels when
evaluating proposals, including funding amounts
requested. Future assessments will be needed to measure
the impact of this guidance, including analyses of how
funding has actually strengthened pharmacovigilance
programmes. Budget estimation recommendations and
links to potential technical assistance partners would
make them even more useful and easily applicable. Delin-
eating the operational details necessary for key method-
ologies such as active surveillance and stimulated
spontaneous reporting could help countries, funders, and
review panels develop the same vocabulary with which to
describe and propose strengthening of pharmacovigi-
lance structures.
Technical assistance to developing countries seeking to
create or enhance their pharmacovigilance systems
should be a streamlined, coordinated effort, and stan-
dardized reporting forms and mechanisms should be
u s e d  a s  m u c h  a s  p o s s i b l e .  M u c h  o f  t h e  i n f r a s t r u c t u r e
needed to support a functional pharmacovigilance sys-
tem is the same as that needed for successful health infor-
matics systems and epidemiologic surveillance. For
programmes such as PMI, pharmacovigilance activities
should be considered for integration into the current
monitoring and evaluation plans, and could be used at
the same sites that support sentinel health system or vec-
tor surveillance. Recognizing that the most effective
pharmacovigilance system is one that is embedded within
the health system and linked with the other functions of
the existing structure, funders and implementing agen-
cies should work collaboratively with other branches of
the health system. This analysis serves as a starting point
for future studies of pharmacovigilance activity levels
globally. The data presented here serve as baseline indica-
tors and should be tracked to measure the impact that
recommendations such as those published by RBM and
other future efforts to emphasize the importance of phar-
macovigilance system strengthening have on their promi-
nence in global health initiatives' agendas.
The lack of consistency in the descriptions of pharma-
covigilance activities and proposed activities (see Addi-
tional file 1) underscores the need for coordinating
funding streams and more specific strategies to assist in
the supporting pharmacovigilance in low-income coun-
tries. RBM recommended that a national pharmacovigi-
lance programme for anti-malarial drugs should cost
between $150,000 and $250,000 USD for start-up with
recurrent costs of around $50,000 per year [20]. This
amount would vary depending on the size of a country
and the state of existing health infrastructure, such as lab-
oratories, which are key components for pharmacovigi-
lance, as well as other health system activities and the
specific activities being proposed. Countries applying for
Global Fund support can request support for pharma-
covigilance activities under Health Systems Strengthen-
ing (HSS) Cross-Cutting Interventions, since a strong
pharmacovigilance system is an integral part of a func-
tioning national health system. Global health initiatives
are now placing a renewed emphasis on HSS in their pro-
gramming goals, providing an opportunity to include
pharmacovigilance activities within this scope.
There were some limitations to this study. This analysis
only presents a snapshot of pharmacovigilance plans and
activities as reflected in country plans and key funding
proposals for malaria control and prevention. As such,
countries' existing pharmacovigilance capabilities and
activities may not have been fully captured in this assess-
ment. The budgets for pharmacovigilance in the Global
Fund Round 8 proposals were not delineated in such a
way as to identify how much funding was requested spe-
cifically for pharmacovigilance activities, so they cannot
be analysed in the same way that the PMI MOPs can.
Descriptions of pharmacovigilance activities and requests
for pharmacovigilance support submitted to other fund-
ing sources were beyond the scope of this analysis. A brief
assessment of the Country Operational Plans (COP) for
2009 submitted by countries that received support from
the U.S. President's Emergency Plan for AIDS ReliefStergachis et al. Malaria Journal 2010, 9:148
http://www.malariajournal.com/content/9/1/148
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Table 3: Comparison of four countries that submitted both GF Round 8 - Malaria and PMI 2009 proposals
Country
Ghana Ethiopia Rwanda Tanzania
PMI FY 
2009 MOP
Global 
Fund 
Round 8
PMI FY 
2009 MOP
Global 
Fund 
Round 8
PMI FY 
2009 MOP
Global 
Fund 
Round 8
PMI FY 
2009 MOP
Global 
Fund 
Round 8
Pharmacovigilance 
programme 
identified in country
No Yes No Yes In initial 
phase of 
devel-
opment
No Not ment-
ioned
No
Section dedicated to 
pharmacovigilance
N o Y e sN o Y e sY e sY e sN o Y e s
Pregnancy registry 
identified in country
No No No No No No No No
Funds requested for 
pharmacovigilance
Y e s N oN oN oY e s N oN oN o
Type of 
pharmacovigilance 
surveillance 
activities mentioned 
in the proposal
Not ment-
ioned
Passive and 
active
Not ment-
ioned
Passive Passive and 
active
Passive Not ment-
ioned
Not ment-
ioned
Agency identified in 
charge of 
pharmacovigilance 
activities
Yes Yes No Yes Yes No No No
(PEPFAR) found no mention of pharmacovigilance plans
or budget requests in the COPs. Also, no information is
presented here as to how the countries used the funds for
pharmacovigilance activities as this was beyond the scope
of this analysis.
In summary, the key finding from the analysis of both
PMI MOPs from FY 2009 as well as GF Round 8 propos-
als was that overall, there is a dearth of requests for fund-
ing for pharmacovigilance programmes, despite
acknowledgement by many in the global health commu-
nity that pharmacovigilance is an integral component of
any national malaria programme and health system as a
whole. Even within the proposals that did include
requests for funding pharmacovigilance programmes, the
amounts were often less than recommended. These find-
ings demonstrate the lack of emphasis placed on pharma-
covigilance system strengthening despite the fact that in
2008 alone, 15.6 million treatment doses for ACT were
procured through PMI in nine of its focus countries [21].
Additionally, it is evident from this analysis that the
understanding of what defines a pharmacovigilance sys-
tem and how much it should cost varies greatly between
countries and their assistance partners who help prepare
requests to their major donors. Both WHO and the
Global Fund are developing a standard set of components
needed for a basic functioning pharmacovigilance sys-
tem. One indicator-based pharmacovigilance assessment
tool has recently been developed and pilot tested through
the Strengthening Pharmaceutical Systems programme
[22]. Pharmacovigilance systems should improve when
stakeholders collaborate on better defining and agreeing
upon performance indicators and inform where impor-
tant gaps exist, allowing for all concerned to contribute
towards improving the safety of medicines. Investing in
pharmacovigilance systems should not only benefit
malaria control and prevention programmes, it should
also ensure that robust surveillance, reporting and labo-
ratory systems are in place for future monitoring of medi-
cations of all kinds.Stergachis et al. Malaria Journal 2010, 9:148
http://www.malariajournal.com/content/9/1/148
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Conclusions
Results from the analysis of both PMI MOPs from FY
2009 as well as GF Round 8 proposals indicate that the
amount of money requested for pharmacovigilance activ-
ities in developing countries do not match up with large-
scale deployment of novel anti-malarial treatments and
global acknowledgement that pharmacovigilance is an
integral component of any national malaria programme
and health system as a whole. Within the proposals that
did include requests for funding pharmacovigilance pro-
grammes, it was difficult to tell what specifically the
funds would be used for , and thus to know if sufficient
amounts were being requested. For example, if a develop-
ing pharmacovigilance system would train and use exist-
ing staff to implement surveillance activities, the costs
would be much lower than if new workers were necessary
to implement the monitoring activities. Finally, there was
considerable inconsistency in the pharmacovigilance ele-
ments described in requests to PMI and the Global Fund.
The format of the proposals themselves, especially the
l a y o u t  o f  t h e  G l o b a l  F u n d  b u d g e ts  m a k e  i t  d i f fi cu l t  t o
know what specifically the funds will be used to do.
Explicitly describing how funds will be used for specific
pharmacovigilance activities will aid in achieving true
transparency and improve the ability to monitor develop-
ment of systems. All these findings demonstrate the lack
of emphasis placed to-date on pharmacovigilance in
recipient countries and among their funding and techni-
c a l  a s s i s t a n c e  p a r t n e r s  a s  w e l l  a s  a  l a c k  o f  s p e c i f i c i t y
about what the funds are being requested for. Enhanced
global guidance and technical assistance could address
these shortcomings and would support country and
donor goals of ensuring access to high quality and safe
treatments for malaria and other conditions. The incon-
sistencies in describing pharmacovigilance activities
between the MOPs and GF proposals of countries that
had both underscore the importance of providing well-
defined expectations, standards, and tools for establish-
ing and evaluating pharmacovigilance systems.
Additional material
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